Why the study?
ARLD affects liver function and hemostasis leading to increased mortality, prompting investigation of the platelet proteome and apoptosis to identify potential biomarkers for disease progression.
Changes in platelet proteomes, including proteins like von Willebrand factor and vitronectin, could serve as noninvasive biomarkers for diagnosing and monitoring alcohol-related liver disease.
Candidate biomarkers merit prospective validation; hypothesis-generating and should not yet change practice in alcohol-related liver disease.
Chronic alcoholism is a significant health issue associated with severe liver complications, including alcohol-related liver disease (ARLD), progresses from fatty liver to cirrhosis and hepatocellular carcinoma. ARLD affects liver function and hemostasis, leading to increased mortality. This study intended to investigate the platelet proteome and detect platelet cell apoptosis via Annexin V in ARLD patients in order to identify potential biomarkers for disease progression. Twenty-three patients with ARLD were recruited, and their platelet proteins were analyzed via mass spectrometry. Approximately 441 proteins were identified, with 73 candidate biomarkers selected on the basis of clinical importance. Key proteins involved in coagulation, inflammation, and cellular interactions are highlighted. Gene ontology and STRING analyses revealed functional clusters and pathways associated with these proteins. This study identified critical platelet proteins, such as von Willebrand factor, vitronectin, and serpin family members, which play essential roles in hemostasis and liver disease pathogenesis. These findings suggest that changes in platelet proteomes could serve as noninvasive biomarkers for diagnosing, monitoring, and treating ARLD.
No takes yet. Share an insight, caveat, or question.
Kademani et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: